<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    15030339
   </pmid>
   <datecreated>
    <year>
     2004
    </year>
    <month>
     03
    </month>
    <day>
     19
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2004
    </year>
    <month>
     05
    </month>
    <day>
     03
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     19
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0007-0963
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       150
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2004
       </year>
       <month>
        Mar
       </month>
      </pubdate>
     </journalissue>
     <title>
      The British journal of dermatology
     </title>
     <isoabbreviation>
      Br. J. Dermatol.
     </isoabbreviation>
    </journal>
    <articletitle>
     Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.
    </articletitle>
    <pagination>
     <medlinepgn>
      537-44
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Onychomycosis is a common nail disease that is often chronic, difficult to eradicate, and has a tendency to recur. The most common oral therapies for dermatophyte toenail onychomycosis include terbinafine, itraconazole and fluconazole.
     </abstracttext>
     <abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">
      A cumulative meta-analysis of the randomized controlled trials (RCTs) for antimycotic agents was performed to determine whether the pooled estimate of the cure rates has remained consistent over the years. Furthermore, for each agent we compared the overall meta-analytical average of both mycological and clinical response rates of RCTs vs. open studies.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      We searched MEDLINE (1966 to November 2002) for relevant studies evaluating the efficacy of the oral antifungal agents terbinafine, itraconazole (pulse or continuous), fluconazole and griseofulvin for treating dermatophyte toenail onychomycosis. Studies included in this meta-analysis required a standard accepted dosage regimen, treatment duration and follow-up period. To determine the cumulative meta-analytical average, studies were sequentially pooled by adding one study at a time according to the date of publication (i.e. earliest to the most recent).
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      There were 36 studies included in the analyses. For RCTs the change in efficacy of mycological cure rates from the first trial to the overall cumulative meta-average for each drug comparator is as follows (with 95% confidence interval): terbinafine, 78 +/- 6% (n = 2 studies, 79 patients) to 76 +/- 3% (n = 18 studies, 993 patients) (P = 0.68); itraconazole pulse, 75 +/- 10% (n = 1 study, 20 patients) to 63 +/- 7% (n = 6 studies, 318 patients) (P = 0.25); itraconazole continuous, 63 +/- 5% (n = 1 study, 84 patients) to 59 +/- 5% (n = 7 studies, 1131 patients) (P = 0.47); fluconazole, 53 +/- 6% (n = 1 study, 72 patients) to 48 +/- 5% (n = 3 studies, 131 patients) (P = 0.50); and griseofulvin, 55 +/- 8% (n = 2 studies, 109 patients) to 60 +/- 6% (n = 3 studies, 167 patients) (P = 0.41). The cumulative meta-analytical average of mycological cure rates when comparing RCTs vs. open studies was: terbinafine, 76 +/- 3% (n = 18 studies, 993 patients) vs. 83 +/- 12% (n = 2 studies, 391 patients) (P = 0.0028); itraconazole pulse, 63 +/- 7% (n = 6 studies, 318 patients) vs. 84 +/- 9% (n = 3 studies, 194 patients) (P = 0.0001); and fluconazole, 48 +/- 5% (n = 3 studies, 131 patients) vs. 79 +/- 3% (n = 3 studies, 208 patients) (P = 0.0001).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The cumulative meta-analysis of cure rates for RCTs suggests that over time, as new RCTs have been conducted, the efficacy rates have remained consistent. The efficacy rates of open studies are substantially higher compared with RCTs and may therefore overestimate cure rates.
     </abstracttext>
    </abstract>
    <affiliation>
     Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook Site) and the University of Toronto, Toronto, Ontario, Canada. agupta@execulink.com
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Gupta
      </lastname>
      <forename>
       A K
      </forename>
      <initials>
       AK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ryder
      </lastname>
      <forename>
       J E
      </forename>
      <initials>
       JE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Johnson
      </lastname>
      <forename>
       A M
      </forename>
      <initials>
       AM
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Meta-Analysis
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     Br J Dermatol
    </medlineta>
    <nlmuniqueid>
     0004041
    </nlmuniqueid>
    <issnlinking>
     0007-0963
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antifungal Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Naphthalenes
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      126-07-8
     </registrynumber>
     <nameofsubstance>
      Griseofulvin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      84625-61-6
     </registrynumber>
     <nameofsubstance>
      Itraconazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      86386-73-4
     </registrynumber>
     <nameofsubstance>
      Fluconazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      91161-71-6
     </registrynumber>
     <nameofsubstance>
      terbinafine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antifungal Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Fluconazole
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Griseofulvin
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Itraconazole
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Naphthalenes
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Onychomycosis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Randomized Controlled Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    83
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2004
     </year>
     <month>
      3
     </month>
     <day>
      20
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2004
     </year>
     <month>
      5
     </month>
     <day>
      5
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2004
     </year>
     <month>
      3
     </month>
     <day>
      20
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     15030339
    </articleid>
    <articleid idtype="doi">
     10.1046/j.1365-2133.2003.05728.x
    </articleid>
    <articleid idtype="pii">
     BJD5728
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

